Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:C07H

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2023/001982MR1 LIGANDS AND PHARMACEUTICAL COMPOSITIONS FOR IMMUNOMODULATION
WO 26.01.2023
Int.Class G01N 33/50
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
Appl.No PCT/EP2022/070541 Applicant UNIVERSITÄT BASEL Inventor FLOHR, Alexander
The present invention relates to ligands specifically presented by MR1 molecules to MR1-specific T cells. These ligands are derivatives or analogues of nucleic acid forming bases, particularly ribonucleoside and deoxyribonucleoside adducts occurring in eukaryotic cells under certain conditions. The invention further relates to pharmaceutical preparations and methods for use of such ligands in treatment and research. The invention further relates to pharmaceutical preparations provided with the aim of modulating presentation of MR1 ligands in clinical situations where such modulated presentation of MR1 ligands is of clinical benefit.
2.WO/2023/000708POLYSUBSTITUTED PURINE COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF
WO 26.01.2023
Int.Class C07D 487/04
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
487Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/-C07D477/183
02in which the condensed system contains two hetero rings
04Ortho-condensed systems
Appl.No PCT/CN2022/083786 Applicant CHINA PHARMACEUTICAL UNIVERSITY Inventor YANG, Peng
Disclosed are a polysubstituted purine compound as shown in formula (I), and a pharmaceutically acceptable salt thereof, a preparation method therefor and the use thereof. Also disclosed is that the compound has an obvious inhibitory effect on RNA adenosine deaminase 1 (ADAR1) and can be used for preventing and/or treating cancer or tumor-related diseases caused by abnormal activity of such enzymes, especially prostate cancer, leukemia, breast cancer, multiple myeloma, lung cancer, stomach cancer, ovarian cancer, colon cancer, liver cancer, pancreatic cancer, human glioma and other diseases.
3.WO/2023/004438FRET-BASED ASSAYS
WO 26.01.2023
Int.Class C07D 401/12
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
401Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
02containing two hetero rings
12linked by a chain containing hetero atoms as chain links
Appl.No PCT/US2022/074087 Applicant THE GENERAL HOSPITAL CORPORATION Inventor MAZITSCHEK, Ralph
The present application provides compounds and methods for identifying a modulator of a protein of interest using TR-FRET donor attached to the protein of interest and a tracer containing TR-FRET acceptor.
4.WO/2023/001004MANNOSE DERIVATIVE AND APPLICATION THEREOF
WO 26.01.2023
Int.Class C07H 13/04
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
13Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
02by carboxylic acids
04having the esterifying carboxyl radicals attached to acyclic carbon atoms
Appl.No PCT/CN2022/104832 Applicant BEIJING NORMAL UNIVERSITY Inventor ZHANG, Junbo
The present invention relates to the technical fields of radiopharmaceutical chemistry and clinical nuclear medicine, and in particular to a mannose derivative and an application thereof. The mannose derivative is an isonitrile-containing mannose derivative which contains different linking groups X and has a structure as shown in a general formula (I). A radioactive preparation obtained by labeling the mannose derivative with radionuclide is high in uptake in tumors and good in tumor/non-target ratio, and is a novel tumor radiopharmaceutical worthy of popularization.
5.WO/2023/002354NEW SYNTHETIC AGONISTS OF TLR4 RECEPTOR
WO 26.01.2023
Int.Class C07F 7/18
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
FACYCLIC, CARBOCYCLIC, OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
7Compounds containing elements of Groups 4 or 14 of the Periodic System
02Silicon compounds
08Compounds having one or more C-Si linkages
18Compounds having one or more C-Si linkages as well as one or more C-O-Si linkages
Appl.No PCT/IB2022/056615 Applicant UNIVERSITÀ DEGLI STUDI DI MILANO - BICOCCA Inventor PERI, Francesco
The present invention relates to new synthetic molecules with agonist activity of human Toll-like Receptor 4 (TLR4), compositions comprising them and uses thereof for the treatment of diseases in which it is useful to induce or increase an immune response. These new syntethic molecules differ from other similar agonists due to the simplicity of the formula, the ease and cheapness of preparation and the possibility of further chemical processing to modify the physicochemical properties and allow conjugation to other molecules (for example protein antigens).
6.WO/2023/002506COMPOSITIONS OF SOPHOROLIPIDS FOR POTENTIAL USE IN THE TREATMENT OF TUBERCULOSIS AND MULTIDRUG RESISTANT TUBERCULOSIS
WO 26.01.2023
Int.Class A61K 31/545
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
54having six-membered rings with at least one nitrogen and at least one sulfur as the ring hetero atoms, e.g. sulthiame
542ortho- or peri-condensed with heterocyclic ring systems
545Compounds containing 5-thia-1-azabicyclo octane ring systems, i.e. compounds containing a ring system of the formula , e.g. cephalosporins, cefaclor, cephalexine
Appl.No PCT/IN2022/050650 Applicant GODREJ INDUSTRIES LTD (CHEMICALS) Inventor GHARAT, Sandeep Dattatray
The present invention discloses compositions comprising Sophorolipids, having anti-tubercular activity for potential use in the treatment of tuberculosis and multidrug resistant tuberculosis. The invention also discloses compositions comprising Sophorolipids and its compatibility with standard anti-tuberculosis drugs for potential use in treatment of tuberculosis and multi-drug resistant tuberculosis as a part of multi-drug regimen.
7.WO/2023/001234MODIFIED SMALL INTERFERING RNA MOLECULES WITH REDUCED OFF-TARGET EFFECTS
WO 26.01.2023
Int.Class C12N 15/11
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
Appl.No PCT/CN2022/107028 Applicant MICROBIO (SHANGHAI) CO., LTD. Inventor CHANG, Yi-Chung
A modified small interfering RNA (siRNA) molecule comprising phosphorothioate (PS) intemucleotide linkages in the antisense strand for reducing off-target effects and methods and uses thereof. The siRNAs targeting Hypoxia Inducible Factor 1 Subunit Alpha (HIFla) with high specificity and silencing efficiency.
8.WO/2023/002509LIPID FORMULATION FOR DELIVERY OF THERAPEUTIC AGENTS
WO 26.01.2023
Int.Class A61K 47/26
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
Appl.No PCT/IN2022/050660 Applicant INSTITUTE FOR STEM CELL SCIENCE AND REGENERATIVE MEDICINE Inventor MAREPALLY, Srujan
The present disclosure provides a formulation comprising a first lipid compound of Formula I; a second lipid compound of Formula II and a co-lipid wherein the first lipid to the second lipid to the co-lipid is in the mole ratio range of 1:0.1:0.1 to 1:4:4. The present disclosure also provides a first lipid compound of Formula I, and a second lipid compound of Formula II. The present disclosure further provides processes for preparing the formulation, the lipid compounds and methods thereof.
9.WO/2023/004130METHODS FOR PREPARING BISPHOSPHOCINS
WO 26.01.2023
Int.Class A61K 31/522
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
519ortho- or peri-condensed with heterocyclic rings
52Purines, e.g. adenine
522having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
Appl.No PCT/US2022/038040 Applicant LAKEWOOD AMEDEX, INC. Inventor COOPER, Kelvin
Methods for synthesizing Bisphosphocins use chemical modification of dialcoholic compounds avoiding the use of tetrazole and tertiary butyl hydroperoxide.
10.WO/2023/000516PURIFICATION METHOD FOR PAEONIFLORIN-6-O'-BENZENE SULFONATE
WO 26.01.2023
Int.Class C07H 1/06
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
1Processes for the preparation of sugar derivatives
06Separation; Purification
Appl.No PCT/CN2021/124535 Applicant GUANGZHOU HANFANG PHARMACEUTICAL CO., LTD. Inventor XU, Wendong
The present invention provides a purification method for paeoniflorin-6-O'-benzene sulfonate. According to the purification method, the purification process for paeoniflorin-6-O'-benzene sulfonate can be reduced, and impurities, such as benzenesulfonyl chloride and derivatives thereof, iron, and heavy metals, in the prepared paeoniflorin-6-O'-benzene sulfonate crude product can be effectively removed, to obtain paeoniflorin-6-O'-benzene sulfonate of which the content is 98% or more. In addition, under the condition of ensuring high content, the energy consumption is low, the solvent dosage is small, the time consumption is low, and the method is thus suitable for industrial production of paeoniflorin-6-O'-benzene sulfonate.